Fierce Biotech August 15, 2022
On biotech’s cutting room floor lies a littering of IV bags and powdery oral pills. Cast off trial documents and FDA regulatory submissions, hastily pulled back, are piling up in the recycling. Befuddled clinicians, suddenly without a clinical trial to conduct or a pipeline candidate to work on, are wandering around.
This, after “a six-month period to forget” in the markets, according to Evaluate Vantage. We’re seeing a seemingly unprecedented reckoning from biotech C-suites, where executives are making tough calls about continuing to keep the lights on or cutting once promising candidates.
Every day of the second quarter earnings reporting period we’ve seen small companies regretfully informing the world that...
Today's Sponsors
Today's Sponsor